Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!

Home
report store
waldenstrom macroglobulinemia epidemiology forecast insight

SALE

Waldenstrom Macroglobulinemia - Epidemiology Forecast to 2034

Published Date : 2025

Pages : 110

Region : United States, Japan, EU4 & UK

SALE

Summary
TOC Table of Content
LOT
- Sample Request

waldenstrom macroglobulinemia epidemiology forecast insight

DelveInsight’s ‘Waldenstrom Macroglobulinemia (WM) – Epidemiology Forecast—2034’ report delivers an in-depth understanding of Waldenstrom Macroglobulinemia, and historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2021-2034

Waldenstrom Macroglobulinemia - Disease Understanding

Waldenstrom Macroglobulinemia, also referred to as a lymphoplasmacytic lymphoma (LPL) with an associated monoclonal IgM paraprotein, is a rare indolent (slow-growing) B-cell lymphoma that occurs in <2% of patients with Non-Hodgkin’s Lymphoma (NHL). WM usually affects older adults and generally affects the bone marrow but can also occur in the lymph nodes and other tissues and organs of the lymphatic system.

Waldenstrom Macroglobulinemia Epidemiology

The Waldenstrom Macroglobulinemia epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for the seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool, trends, and assumptions.

Key Findings

The total incident cases of Waldenstrom Macroglobulinemia patients are increasing in 7MM during the study period, i.e., 2021-2034.

The disease epidemiology covered in the report provides historical as well as forecasted WM symptoms epidemiology segmented as the Incidence of Waldenstrom Macroglobulinemia, Gender-specific cases of Waldenstrom Macroglobulinemia, Age-specific Cases of Waldenstrom Macroglobulinemia, and Genetic Mutations in Waldenstrom Macroglobulinemia. The report includes the incident scenario of Waldenstrom Macroglobulinemia symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2021 to 2034.

Country-wise Waldenstrom Macroglobulinemia Epidemiology

The epidemiology segment also provides the Waldenstrom Macroglobulinemia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The incident cases of Waldenstrom Macroglobulinemia associated in 7MM countries were 3,159 in 2020.
As per the estimates, the United States has the largest incident population of Waldenstrom Macroglobulinemia.
Among the EU5 countries, France had the highest incident cases of Waldenstrom Macroglobulinemia, followed by the UK. On the other hand, Spain had the lowest incident cases with 154 cases in 2020.

Scope of the Report

The Waldenstrom Macroglobulinemia (WM) report covers a detailed overview explaining its causes, symptoms, and classification, pathophysiology, diagnosis, and treatment patterns.
The Waldenstrom Macroglobulinemia (WM) Epidemiology Report and Model provide an overview of Waldenstrom Macroglobulinemia’s risk factors and global trends in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
The report provides insight into WM’s historical and forecasted patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
The report assesses the disease risk and burden and highlights the unmet needs of Waldenstrom Macroglobulinemia.
The report provides the segmentation of Waldenstrom Macroglobulinemia epidemiology by the incidence of Waldenstrom Macroglobulinemia in 7MM.
The report provides the Waldenstrom Macroglobulinemia epidemiology segmentation by Gender-specific cases in 7MM.
The report provides the Waldenstrom Macroglobulinemia epidemiology segmentation by Age-specific Cases in 7MM.
The report provides the Waldenstrom Macroglobulinemia epidemiology segmentation by Genetic Mutations in 7MM.

Report Highlights

10-year Forecast of Waldenstrom Macroglobulinemia epidemiology
7MM Coverage
Incidence of Waldenstrom Macroglobulinemia
Gender-specific cases of Waldenstrom Macroglobulinemia
Age-specific Cases of Waldenstrom Macroglobulinemia
Genetic Mutations in Waldenstrom Macroglobulinemia

KOL Views

We interview KOLs, and SMEs’ opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

What will be the growth opportunities in the 7MM for the patient population about Waldenstrom Macroglobulinemia?
What are the key findings of the Waldenstrom Macroglobulinemia epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2021-2034)?
What would be the total number of Waldenstrom Macroglobulinemia patients across the 7MM during the forecast period (2021-2034)?
Among the EU5 countries, which country will have the highest number of patients during the forecast period (2021-2034)?
At what CAGR the patient population is expected to grow in 7MM during the forecast period (2021-2034)?
What are the disease risk, burden, and unmet needs of Waldenstrom Macroglobulinemia?
What are the currently available treatments for Waldenstrom Macroglobulinemia?

Reasons to buy

The Waldenstrom Macroglobulinemia (WM) epidemiology report will allow the user to -
Develop business strategies by understanding the trends shaping and driving the global Waldenstrom Macroglobulinemia market.
Quantify patient populations in the global Waldenstrom Macroglobulinemia market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Waldenstrom Macroglobulinemia therapeutics in each of the markets covered.
Understand the magnitude of the Waldenstrom Macroglobulinemia population by its incidence.
Understand the magnitude of the Waldenstrom Macroglobulinemia population by its Gender-specific cases.
Understand the magnitude of the Waldenstrom Macroglobulinemia population by its Age-specific cases.
Understand the magnitude of the Waldenstrom Macroglobulinemia population by its Genetic Mutations.
The Waldenstrom Macroglobulinemia epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
The Waldenstrom Macroglobulinemia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Key Assessments

Patient Segmentation
Disease Risk and Burden
Risk of disease by the segmentation
Factors driving growth in a specific patient population

List of Tables:

List of Table

Table 1: Summary of Waldenstrom Macroglobulinemia, Market, Epidemiology, and Key Events (2021-2034)

Table 2: Clinical Manifestations of Waldenstrom macroglobulinemia (WM)

Table 3: Risk Groups involved in Waldenstrom Macroglobulinemia

Table 4: Prognostic Staging Systems in Waldenstrom Macroglobulinemia

Table 5: Diagnostic Approach to Suspected Waldenstrom Macroglobulinemia

Table 6: Differential diagnosis of WM

Table 7: Diagnostic Workup

Table 8: Indications for initiation of therapy in patients with WM

Table 9: Treatment options in first-line according to disease presentation

Table 10: Total Incident Population of WM in 7MM (2021-2034)

Table 11: Incident Cases of WM in the United States (2021-2034)

Table 12: Gender-specific cases of WM in the United States (2021-2034)

Table 13: Age-specific Cases of WM in the United States (2021-2034)

Table 14: Gene Mutations in WM in the United States (2021-2034)

Table 15: Incident Cases of WM in Germany (2021-2034)

Table 16: Gender-specific cases of WM in Germany (2021-2034)

Table 17: Age-specific Cases of WM in Germany (2021-2034)

Table 18: Gene Mutations in WM in Germany (2021-2034)

Table 19: Incident Cases of WM in France (2021-2034)

Table 20: Gender-specific cases of WM in France (2021-2034)

Table 21: Age-specific Cases of WM in France (2021-2034)

Table 22: Gene Mutations in WM in France (2021-2034)

Table 23: Incident Cases of WM in Italy (2021-2034)

Table 24: Gender-specific cases of WM in Italy (2021-2034)

Table 25: Age-specific Cases of WM in Italy (2021-2034)

Table 26: Gene Mutations in WM in Italy (2021-2034)

Table 27: Incident Cases of WM in Spain (2021-2034)

Table 28: Gender-specific cases of WM in Spain (2021-2034)

Table 29: Age-specific Cases of WM in Spain (2021-2034)

Table 30: Gene Mutations in WM in Spain (2021-2034)

Table 31: Incident Cases of WM in the United Kingdom (2021-2034)

Table 32: Gender-specific cases of WM in the United Kingdom (2021-2034)

Table 33: Age-specific Cases of WM in the United Kingdom (2021-2034)

Table 34: Gene Mutations in WM in the United Kingdom (2021-2034)

Table 35: Incident Cases of WM in Japan (2021-2034)

Table 36: Gender-specific cases of WM in Japan (2021-2034)

Table 37: Age-specific Cases of WM in Japan (2021-2034)

Table 38: Gene Mutations in WM in Japan (2021-2034)

List of Figures:

List of Figures

Figure 1: Lymphatic System

Figure 2: Clinical Manifestations of Waldenstrom Macroglobulinemia

Figure 3: Risk Factors Involved in Waldenstrom Macroglobulinemia

Figure 4: Mechanism Involved in the Pathogenesis of Waldenstrom Macroglobulinemia

Figure 5: MYD88-dependent Signaling Pathway

Figure 6: Schematic Overview of CXCR4 Signaling

Figure 7: WHO Diagnostic Criteria for Waldenstrom Macroglobulinemia

Figure 8: Classes of agents used in the treatment of Waldenstrom Macroglobulinemia

Figure 9: Guide to the primary therapy of WM

Figure 10: Genomic-based treatment algorithm for symptomatic, previously treated, or refractory patients with WM

Figure 11: Treatment algorithm for patients with newly diagnosed WM

Figure 12: Treatment algorithm for patients with relapsed or refractory WM

Figure 13: Treatment algorithm for WM

Figure 14: Total Incident Population of WM in 7MM (2021-2034)

Figure 15: Incident Cases of WM in the United States (2021-2034)

Figure 16: Gender-specific cases of WM in the United States (2021-2034)

Figure 17: Age-specific Cases of WM in the United States (2021-2034)

Figure 18: Gene Mutations in WM in the United States (2021-2034)

Figure 19: Incident Cases of WM in Germany (2021-2034)

Figure 20: Gender-specific cases of WM in Germany (2021-2034)

Figure 21: Age-specific Cases of WM in Germany (2021-2034)

Figure 22: Gene Mutations in WM in Germany (2021-2034)

Figure 23: Incident Cases of WM in France (2021-2034)

Figure 24: Gender-specific cases of WM in France (2021-2034)

Figure 25: Age-specific Cases of WM in France (2021-2034)

Figure 26: Gene Mutations in WM in France (2021-2034)

Figure 27: Incident Cases of WM in Italy (2021-2034)

Figure 28: Gender-specific cases of WM in Italy (2021-2034)

Figure 29: Age-specific Cases of WM in Italy (2021-2034)

Figure 30: Gene Mutations in WM in Italy (2021-2034)

Figure 31: Incident Cases of WM in Spain (2021-2034)

Figure 32: Gender-specific cases of WM in Spain (2021-2034)

Figure 33: Age-specific Cases of WM in Spain (2021-2034)

Figure 34: Gene Mutations in WM in Spain (2021-2034)

Figure 35: Incident Cases of WM in the United Kingdom (2021-2034)

Figure 36: Gender-specific cases of WM in the United Kingdom (2021-2034)

Figure 37: Age-specific Cases of WM in the United Kingdom (2021-2034)

Figure 38: Gene Mutations in WM in the United Kingdom (2021-2034)

Figure 39: Incident Cases of WM in Japan (2021-2034)

Figure 40: Gender-specific cases of WM in Japan (2021-2034)

Figure 41: Age-specific Cases of WM in Japan (2021-2034)

Figure 42: Gene Mutations in WM in Japan (2021-2034)

Tags:

License Type

Offer

waldenstrom macroglobulinemia epidemiology forecast insight Sample Page

Get a Sneak Peek at the Latest waldenstrom macroglobulinemia epidemiology forecast insight Report

Request Sample

View Pricing

Customize Reports As Per Your Needs

Don't see what you're looking for? Get a report tailored to your specific requirements. Customize your report now!

ESMO Conference 2024

Live Coverage of ESMO 2024 Visit Now for Real-Time Insights and Analytical, Impactful Updates!

Have a Question?

We are happy to assist you.

+91-9650213330

info@delveinsight.com

DelveInsight
SUBSCRIPTION
Platform